Abstract
The administration of pronase prior to gastroscopy enhances visual field clarity, reduces examination time, and increases the detection rates of precancerous lesions and early cancer.
Introduction
Gastric cancer remains a leading cause of cancer-related mortality, largely due to late-stage diagnosis. In regions like China, the early detection rate is significantly lower than in countries with established screening protocols, such as Japan. A primary obstacle during gastroscopy—the gold standard for screening—is the natural presence of thick mucus and bubbles on the stomach lining. This coating obscures the endoscopist's view, potentially hiding subtle, minimal-change lesions indicative of early-stage malignancy. While manual rinsing during the procedure is common, it is time-consuming and often insufficient. This study evaluates the efficacy of pronase, a proteolytic enzyme, in chemically dissolving this mucus barrier prior to examination.
Methods
A cluster randomized controlled trial was conducted in Wuwei, China, involving 1,450 participants aged 40 to 70. This region is characterized by a high incidence of gastric cancer.
- Experimental Group (n=725): Received a solution of pronase, sodium bicarbonate, and dimethicone 15–30 minutes before gastroscopy. Pronase acts by cleaving glycoprotein bonds to dissolve mucus, while dimethicone serves as a defoaming agent.
- Control Group (n=725): Received only dimethicone.
Visibility was scored on a scale of 1 (excellent) to 4 (poor) across multiple gastric regions by experienced endoscopists. The primary outcomes measured were total examination time and the detection rates of precancerous lesions and early-stage cancers, confirmed via biopsy.
Results
Enhanced Visual Clarity
The use of pronase significantly improved mucosal visibility. The experimental group achieved near-perfect visibility scores (mean ~1.1) across all examined regions, including the oesophagus, cardia, and gastric body. In contrast, the control group exhibited significantly higher scores (2.0 to 3.0), indicating blurred fields that required manual rinsing.
Improved Detection Rates
The improved visibility directly translated into higher diagnostic yields. The overall detection rate for lesions was 77.5% in the pronase group compared to 62.5% in the control group (P < 0.001). Notably, the detection of early-stage cancer was higher in the experimental group (3.0% vs. 2.1%). After adjusting for confounding factors such as smoking and family history, patients in the pronase group were found to have a 3.84-fold higher likelihood of early cancer detection (OR = 3.840, P = 0.023).
Efficiency and Safety
Pre-treatment with pronase reduced the average gastroscopy time by approximately 35%, from 10.03 minutes to 6.52 minutes. This efficiency gain is attributed to the reduced need for intra-procedural rinsing. Furthermore, the intervention was well-tolerated, with no adverse reactions reported in either group.
Conclusion
The administration of pronase before gastroscopy is a safe, low-cost, and highly effective intervention. By providing a pristine visual field, it enables the detection of subtle precancerous and early malignant lesions that might otherwise be missed. While further large-scale multi-center studies are warranted to standardize its use, these findings suggest that pronase should be considered a standard adjunct in routine clinical gastroscopy for high-risk populations.
Summary updated